Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 2 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 2 of 8.)

DateHeadlineEventSource5-minTo close
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual MeetingPress releasePR Newswire+0.80%+1.43%
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialPress releasePR Newswire-0.02%+1.43%
Form 8-K ELI LILLY & Co For: May 20SEC filing · Form 8-KSEC EDGAR-0.02%+1.43%
Lilly to participate in Bernstein's 42nd Annual Strategic Decisions ConferencePress releasePR Newswire-0.31%-0.58%
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youthPress releasePR Newswire-1.27%-1.25%
Lilly and UNICEF collaborate to give millions of children a healthier startPress releasePR Newswire-1.13%-1.06%
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesPress releasePR Newswire-0.26%-0.32%
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsPress releasePR Newswire-0.16%+1.97%
Form SD ELI LILLY & CoSEC filing · Form SDSEC EDGAR+0.02%+1.52%
The Next Generation of the GLP-1 Revolution Is Already UnderwayPress releaseGlobeNewswire+2.16%+2.34%
Form 8-K ELI LILLY & Co For: May 04SEC filing · Form 8-KSEC EDGAR-0.07%-2.63%
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facilityPress releasePR Newswire-0.53%-0.43%
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four yearsPress releasePR Newswire-0.28%+1.74%
HEALTH CANADA AUTHORIZES LILLY'S KISUNLA™ (DONANEMAB), A NEW TREATMENT FOR EARLY ALZHEIMER'S DISEASEPress releaseCanada Newswire+0.90%+0.94%
Lilly declares second-quarter 2026 dividendPress releasePR Newswire-0.00%+0.76%
PDA Releases Revised Technical Reports on Process Validation and Biologics Reprocessing to Support Manufacturing ExcellencePress releasePR Web+0.90%+0.94%
Form 10-Q ELI LILLY & Co For: Mar 31SEC filing · Form 10-QSEC EDGAR+0.01%+1.36%
Form 8-K ELI LILLY & Co For: Apr 30SEC filing · Form 8-KSEC EDGAR+0.60%+3.84%
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicinesPress releasePR Newswire+0.60%+3.84%
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia veraPress releasePR Newswire+0.98%-0.77%
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialPress releaseGlobeNewswire-0.25%-1.06%
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapiesPress releasePR Newswire-0.06%-0.66%
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic healthPress releasePR Newswire+0.55%-0.66%
Lilly confirms date and conference call for first-quarter 2026 financial results announcementPress releasePR Newswire-0.15%-1.11%
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLLPress releasePR Newswire-0.52%-0.90%
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.Press releasePR Newswire+0.23%+0.91%
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsPress releasePR Newswire-0.24%-0.43%
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPress releasePR Newswire+1.93%+2.94%
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesityPress releasePR Newswire+0.18%-0.07%
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitisPress releasePR Newswire+0.04%-1.98%
Form DEF 14A ELI LILLY & Co For: Mar 20SEC filing · Form DEFSEC EDGAR-0.11%-0.48%
Form DEFA14A ELI LILLY & CoSEC filing · Form DEFA14ASEC EDGAR-0.11%-0.48%
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetesPress releasePR Newswire+0.61%+0.38%
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitisPress releasePR Newswire-0.15%-0.29%
Form PRE 14A ELI LILLY & Co For: Mar 06SEC filing · Form PRESEC EDGAR-0.16%+2.18%
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patientsPress releasePR Newswire+0.13%-0.68%
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areataPress releasePR Newswire+0.88%+3.40%
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsightPress releasePR Newswire+0.88%+3.40%
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The LancetPress releasePR Newswire-0.27%-0.20%
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPenPress releasePR Newswire-0.96%+1.09%
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)Press releasePR Newswire+0.14%+0.79%
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweightPress releasePR Newswire-0.45%-1.14%
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and CompanyPress releaseBusiness Wire+0.37%-0.91%
Lilly to participate in TD Cowen's 46th Annual Health Care ConferencePress releasePR Newswire+0.37%-0.91%
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancerPress releasePR Newswire+0.37%-0.91%
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and CompanyPress releasePR Newswire+0.37%-0.91%
Form 10-K ELI LILLY & Co For: Dec 31SEC filing · Form 10-KSEC EDGAR+0.06%-0.82%
Lilly to acquire Orna Therapeutics to advance cell therapiesPress releasePR Newswire+1.74%-3.36%
Form 8-K ELI LILLY & Co For: Feb 04SEC filing · Form 8-KSEC EDGAR+0.26%+2.80%
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidancePress releasePR Newswire+0.26%+2.80%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground